中
Home
About Us
About Haihe Biopharma
Mission and Vision
Management Team
Company Milestones
Awards
Research & Development
Strong, Innovation-driven R&D Capabilities
R&D Pipeline
Investor Partnerships & BD
Investors
Business Development
News Center
News
Interview
Career
Our Culture
Salary and Benefits
Employee
Job
中文
日本語
News Center
Press Release
页索引超出范围
Press Release
2019.08.26
HaiHe Biopharma Cooperates with Junshi Biosciences to Explore the Combination of Glumetinib and Toripalimab
2019.08.19
HaiHe Biopharma Obtains a World-wide Exclusive License from Shanghai Institute of Materia Medica and Jinan University for a New Anti-Tumor Drug
2019.07.19
First subject recently dosed in the Phase II clinical trial of simmitecan LP-201 by HaiHe Biopharma in the treatment of neuroendocrine carcinoma
2019.05.01
HaiHe Biopharma’s Oral Paclitaxel RMX3001 has recently completed the first subject administration for the treatment of advanced gastric cancer phase III clinical trial
2019.03.05
HaiHe Biopharma Accomplished First Subject Enrollment of LP-X Pivotal Phase II Clinical Trial for Simmitecan
2019.02.11
HaiHe Biopharma Reached $146.6 Million Financing Agreement
2019.01.23
HaiHe Biopharma Accomplished First Subject Enrollment ofLucitanib AL3810-202 for Pivotal Phase IIb Clinical Trial for Thymic Cancer.
2018.12.08
Convened the National Investigator Meeting on the Pivotal Phase III Clinical Trial of Oral Paclitaxel RMX3001 for Treatment of Breast Cancer.
5
6
7
Interview
|
Legal statement
|
Disclaimers
|
Contact
|
Follow Us
©
2020 All Rights Reserved Haihe Biopharma Co., Ltd.
沪ICP备12016151号-1
.jpg)
